Introduction
To survive in a competitive milieu, bacteria generate a variety of antimicrobial agents that are toxic to rival species. Many clinically important antibiotics, such as penicillin, actinomycin, and vancomycin, contain peptide scaffolds that are generated by bacterial non-ribosomal peptide synthetases (Mootz et al, 2002) . Other antibiotics contain ribosomally synthesized peptides, including the low-molecular weight microcins . Microcins are posttranslationally modified peptides that inhibit growth of competing Gram-negative bacteria, such as Escherichia, Salmonella, and Enterobacter, at nanomolar concentrations (Duquesne et al, 2007) . Microcin C7 (MccC7, Figure 1A ), a heptapeptide with an N-formylated methionine, an aminopropyl moiety, and a C-terminal phosphoramidate linkage to adenosine (Guijarro et al, 1995) , is produced by Escherichia coli to eradicate competitor strains through a 'Trojan horse' mechanism. After import into target cells, the peptide framework of MccC7 is cleaved by non-specific peptidases to release a toxic adenylated-aspartic-acid mimic that targets aspartyltRNA synthetase, and thereby inhibits protein synthesis (Metlitskaya et al, 2006) .
Understanding the biosynthetic pathways of natural products, such as MccC7, allows us to gain insights into enzyme mechanism, provides opportunities for developing new antibiotics, and gives new prospects for protein design aimed at generating novel biologically active compounds. MccC7 is generated by two posttranslational modifications of a precursor ribosomal heptapeptide, MccA, featuring the sequence MRTGNAN. Posttranslational steps in MccC7 biosynthesis involve the conversion of the C-terminal Asn 7 to an Asp amide, in which the nitrogen is linked by a phosphoramidate bond to adenosine monophosphate (AMP), followed by aminopropylation of one of the phosphate oxygens. The migration of the Asn 7 carboxamido nitrogen and the N-P bond-forming step are catalysed in a Mg 2 þ -dependent manner by the enzyme MccB ( Figure 1B ) (Roush et al, 2008) . First, in a conventional acyl-adenylation reaction that consumes one adenosine triphosphate (ATP) molecule, MccB catalyses adenylation of the C-terminus of MccA. The resulting MccA-acyl-adenylate then undergoes intramolecular rearrangement, during which AMP is expelled by the carboxamido nitrogen of Asn 7 as a peptidyl-succinimide intermediate is formed. Next, MccB catalyses an unusual adenylation of the succinimide: the succinimidyl nitrogen attacks the a-phosphate of a second ATP molecule. This links the AMP moiety to the peptide terminus through an N-P bond. The succinimide ring is hydrolysed by regiospecific water-mediated opening to yield the peptidyl-acyl-N-Padenosine group, which is the Trojan horse reagent. Unlike acyl-adenylate complexes, which are hydrolytically labilemixed acyl-phosphoric anhydrides, the phosphoramidatelinked analogue of aspartic acyl-adenylate ( Figure 1B ) is hydrolytically stable, allowing persistence throughout the remainder of the MccC7 biosynthetic pathway (aminopropylation, export by the producing cell and import by a sensitive bacterial cell) and ultimate toxic inhibition of aspartyl-tRNA synthetase and protein synthesis in competing bacteria.
The 351-residue MccB has two discernible regions of sequence. The N-terminal (B90 residues) region is not detectably homologous to known structures. The C-terminal (B260 residues) region shares homology with the adenylation domain portion of ubiquitin-like (UBL) protein-activating enzymes, also called E1s, which initiate UBL conjugation ( Supplementary Figures 1 and 2 ). MccB-catalysed adenylation of the MccA C-terminus is reminiscent of the first E1-catalysed reaction, which is the C-terminal adenylation of UBL substrates. However, the substrates of MccB and E1s are markedly divergent. Although MccB catalyses C-terminal transformation of a peptide destined for secretion to combat other organisms, substrates of E1s are proteins that serve as sulphur carriers during biosynthetic pathways, or as covalent protein modifiers (Hochstrasser, 2000 (Hochstrasser, , 2009 .
The sequence similarity between MccB and UBL-activating enzymes raises several questions about common and divergent aspects of the MccB mechanism. First, how does MccB recognize a short-peptide substrate, when all other family members have a X8 kDa UBL protein substrate? Second, why does MccB catalyse adenylation of a peptide harbouring a C-terminal Asn or succinimide, rather than the Gly-Gly sequence found at the C-termini of UBLs? Third, how can MccB catalyse two successive adenylation reactions? To address these questions, we performed structural, biophysical, and biochemical analyses of MccB-MccA-nucleotide interactions.
Results and discussion

Overall structure of MccB
We determined crystal structures of MccB separately and in complex with the following ligands: (1) MccA (first-peptide substrate), (2) MgATP (nucleotide substrate and divalent metal required for catalysis), (3) MccA and a,b-methylene ATP (AMPCPP) (first-peptide substrate and non-hydrolysable ATP analogue), (4) MccA-succinimide (second-peptide substrate), and (5) MccA-N7isoAsn (inhibitor) (Roush et al, 2008) (Figure 1C and D; Table I ; Supplementary Figure 3) . All asymmetric units contain two nearly identical MccB homodimers, with chains designated as A-B or C-D. Thus, the six structures presented here contain a total of 12 homodimers and 24 protomers. The 12 A-B and C-D homodimers superimpose with a Ca root mean square deviation (RMSD) of 76 Å . Owing to this structural similarity, our discussion focuses on chains A-B. The MccB homodimer has an elongated shape. Each homodimer has two parallel, two-domain 'active units'. Each 'active unit' contains an adenylation domain and a globular domain not found in other E1 enzymes. These domains are generated from parts of both protomers in the homodimer (Figure 2 ).
For the adenylation domain, the two parallel halves comprise residues (1) A104-A260, A287-A351, B90-B103 and (2) B104-B260, B287-B351, A90-A103. Each half includes a Rossmann-fold ATP-binding cleft. A five-stranded b-sheet, stabilized by an adjacent zinc-binding site, forms a concave peptide-binding surface. Both halves, individually and together, superimpose with the homologous regions of the bacterial UBL-activating enzymes MoeB and ThiF with Ca RMSDs of 1.5 Å over half and 1.7 Å over the dimer (Lake et al, 2001; Duda et al, 2005) , and with the eukaryotic E1s UBA1, NAE1-UBA3, and SAE1-UBA2 with Ca RMSDs of 1.8-1.9 Å over half and 2.1 Å over the dimer (Walden et al, 2003b; Lois and Lima, 2005; Lee and Schindelin, 2008) .
The unique MccB domain is formed by the coupling of two separated regions of the MccB sequence: the N-terminal residues 1-87 from one monomer and residues 261-287 from the opposite protomer within the homodimeric assembly (Supplementary Figure 1) . This latter region corresponds to an E1 enzyme 'crossover loop', which crosses over the C-terminal tail from the associated UBL (Lake et al, 2001; Walden et al, 2003a; Lois and Lima, 2005; Lee and Schindelin, 2008) . In MccB, the 'crossover loop' is incorporated into the MccB-specific domain, which adopts a structure loosely related to a winged-helix fold. In our peptide co-crystal structures, numerous contacts are observed between this domain and the associated peptides. Thus, we refer to this domain as the 'peptide clamp', owing to its interactions with MccA.
The adenylation and peptide clamp domains pack together in a manner resembling a clamshell. In the overall assembly of an 'active unit', each domain would represent half the shell, which together generate a large central groove that cradles the ATP and peptide substrates (Figure 2 To test the functional importance of the peptide clamp domain, we performed enzymatic assays on mutant versions of MccB. Deleting the MccB N-terminal extension (DNTE), which comprises the bulk of the peptide clamp domain, completely eliminates the activity ( Figure 3B ; Supplementary Figure 4) . To test whether a DNTE mutant has an intact adenylation domain assembly, we assayed homodimerization by analytical ultracentrifugation (AUC). As the AUC data indicate dimerization, reflecting proper folding (Supplementary Figure 5) , we tested whether adding a 10-kDa protein fragment corresponding to MccB's N-terminal 87 residues (NTE) could restore any activity to the DNTE mutant in trans. Approximately 20% of the wild-type (WT) activity was restored ( Figure 3B ; Table II ). These results support the importance of the peptide clamp domain, and indicate that the adenylation and peptide clamp domains work together optimally when expressed as a single unit.
Certain MccB residues from both the clamp and adenylation domains contact the peptides in all the co-crystal structures ( Figure 4 ). Two such residues from the clamp domain are K10 and E26. MccB's K10 directly contacts the carbonyl oxygen from G 4 and the T 3 side chain from MccA and the succinimide. This latter interaction may have a function in constraining the sequences allowed at MccA position 3 during MccC7 biosynthesis . The MccB-K10A mutant has little effect on catalytic rate, but has an increase in the K m of MccA (Table II) , which further shows its importance for peptide binding.
Residues in the adenylation domain form a pocket, in which the N-terminus of the peptides binds. The peptide N-terminal Met 1 adopts a similar conformation in all the complexes, and is encircled by a deep hydrophobic channel generated by residues I243, V245, W326, and H333. The carbonyl of the peptide Met 1 participates in a hydrogen bonding network with R322 and Q335 (Figure 4 ). In the absence of peptide (as in the ATP-bound structure), R322 and Q335 are bound to the solvent.
Past Met 1 , the next four peptide residues follow related trajectories towards the adenylation-active site. Although none of these structurally represents a catalytic intermediate, the C-terminus of the succinimide peptide comes close to approaching the adenylation-active site. In the crystals, the C-terminus of the peptide substrate MccA occupies several locations, none of which is as close to the adenylation-active site as the succinimide. A different backbone conformation is observed for the MccA-N7isoAsn inhibitor, which is a subtle variant of the first-peptide substrate. Residues Thr 3 -Asn 5 of the inhibitor are 'looped out' by one residue relative to the corresponding substrate structures, such that the Ala 6 -isoAsn 7 backbone aligns with Asn 5 -Ala 6 from the succinimide peptide. Thus, the C-terminus of MccA-N7isoAsn does not come as close to the adenylation-active site as the succinimide peptide. The conformational variability observed at the C-termini of the peptides will be discussed below.
Comparison of the peptide-MccB structures with UBLs complexed with their activating enzymes (Lake et al, 2001; Walden et al, 2003a; Lois and Lima, 2005; Lehmann et al, 2006; Huang et al, 2007; Lee and Schindelin, 2008) reveals that the MccA-derived peptides resemble the last seven residues of E1-bound UBLs (Supplementary Figure 6) . Thus, it seems that the unique MccB peptide clamping mechanisms direct substrates to an E1-like active site. (94) is provided by the opposite monomer in the complex. Mutation of the Arg finger to alanine (R94A) has no significant effect on the k cat , but increases the K m for both MccA and ATP (Table II) . Mg 2 þ is coordinated by the three ATP phosphates and D214. D214 is absolutely conserved as an Asp in all UBLactivating enzymes (Supplementary Figure 2) . The corresponding Asp residue was shown earlier to be essential for catalysis by the UBL-activating enzymes E. coli MoeB and the human NEDD8 E1 (Lake et al, 2001; Walden et al, 2003b) . Furthermore, mutation of the corresponding Asp in the ubiquitin E1, UBA1, had pleiotropic effects, including increasing the K m for ATP and ubiquitin and decreasing the k cat for many steps in ubiquitination (Tokgoz et al, 2006) . The earlier studies on UBA1 support a dual function of the Asp in binding MgATP and transition state stabilization (Tokgoz et al, 2006) . The MccB residue D214 is essential for catalysis; we were unable to detect conversion of MccA to succinimide or product by the D214A mutant. (Figure 5B ). However, coincubation of the D214A and DNTE mutants with MccA yields activity similar to mixing the isolated NTE with the DNTE mutant (Supplementary Figure 8) . The former result could either be explained by complementation in trans or by a low concentration of mixed dimers in which DNTE would contribute the catalytic D214, and the full-length version harbouring the D214A mutation would contribute a peptide clamp to form one complete-active site per heterodimer. In either case, the finding of limited activity indicates the importance of the adenylation-active site working in concert with the peptide clamp domain.
Adenylation-active site
Unique features of the MccB-active site
In addition to the shared properties with E1s, the MccB Y239 stands out as being unique in the adenylation catalytic site. Y239 contacts both the ATP a-phosphate and the heptapeptide substrate C-terminus ( Figure 5A ). Y239 is located on the opposite side of MccA from the Mg 2 þ -coordinating D214. Together, Y239 and D214 seem to form a bridge. The MccA and succinimide peptide substrates would need to pass into a channel under the D214-Y239 bridge for adenylation. Y239 has an important catalytic role, as illustrated by the Bfivefold increase in K m for both ATP and MccA and 4600-fold decrease in k cat in the Y239A mutant (Table II; Figure 5C ).
Notably, the MccA C-terminus is atypical among substrates of UBL-activating enzymes as not terminating in the sequence Gly-Gly. Structural comparison reveals that UBL penultimate Glys are oriented by a key E1 Arg, which is lacking and substituted with I220 in MccB. MccB's aforemen- 
MccB (WT) (Roush et al, 2008 tioned unique Y239 may also prevent Gly-Gly recognition. The corresponding E1 residue is a small Ala or Thr, which allows proper orientation of a UBL C-terminal Gly-Gly. In contrast, the MccB adenylation-active site is slightly displaced as compared with UBL-activating enzymes, with Y239 altering the conformation of the MccA-contacting bstrand13, and obscuring the path taken by a UBL Gly-Gly (Supplementary Figure 9) . The channel leading under the D214-Y239 bridge and towards ATP is lined with backbone hydroxyls, which may also favour binding to MccA's C-terminal Asn, and prevent binding of closely related peptides as observed for MccA-N7D (Roush et al, 2008) .
Successive adenylation reactions at a common-active site A striking feature of the MccB mechanism is the usage of two ATP molecules per catalytic cycle: one for the adenylation of
MccA and the second for the formation of the N-P bond through the adenylation of the succinimide intermediate (Roush et al, 2008) . The mutants D214A and Y239A have significant reductions in overall turnover ( Figure 5B and C); we were unable to detect any product formation by D214A starting from the heptapeptide substrate MccA ( Figure 5B ). The structural data suggests that there is one common-active site for MccA and the succinimide intermediate, so we therefore evaluated the processing for the synthetic peptidyl-succinimide intermediate on the second half reaction with our most deleterious point mutants, D214A and Y239A. The detection limit for high-performance liquid chromatography (HPLC) assays was 10 pmol of MccB product, which amounted to a rate of 0.01% of WT enzyme over a 24-h time period. The conversion of the succinimide intermediate to product, representing the second ATP consumption step, occurs 40 times faster than the overall reaction starting with MccA (Roush et al, 2008) . Therefore, assaying the mutants with the succinimide intermediate is more sensitive. On incubation of WT MccB (0.1 mM), or the D214A or Y239A mutants at 150-fold higher enzyme concentrations (15 mM) to magnify sensitivity with 100 mM peptidyl-succinimide, product formation was detected ( Figure 5D ). D214A was B150-fold slower than WT, and Y239A was B600-fold slower than WT MccB in this second half reaction. Therefore, the D214A and Y239A mutations markedly affect both overall turnover and the peptidyl-succinimide to acyl-phosphoramidate product step. As the peptidyl-succinimide does not accumulate in assays of D214A and Y239A starting with MccA (data not shown), we intuit that both the first and the second ATP-using steps are slowed down more than two orders of magnitude and that the formation of the heptapeptidyl-AMP, the cyclization to the succinimide, and the rearrangement to the final N-P-linked product occur in the same active site.
Conformational variability of MccB, MccA-derived heptapeptides, and nucleotide
Comparing the different structures reveals that all three components-MccB, MccA, and nucleotide-display conformational variability (Figure 6 ). MccB conformational flexibility occurs both at a global and a local level. Superposition of the adenylation domains of the different structures reveals that the adenylation and peptide clamp domains can adopt a range of orientations with respect to each other, opening and closing as for two halves of a clamshell ( Figure 6A ). Despite this flexibility, there are many connections between the two domains. As an example, N241 projects away from the MccB adenylation domain to coordinate with the location of peptide clamp domain. This link has a function in the reaction as substitution with Ala decreases k cat five-fold and increases K m Bsix-fold for both MccA and ATP (Supplementary  Tables I-III) .
There is also extensive local flexibility at the adenylationactive site. Side-chain positions of ATP-binding residues, such as R94, and a key catalytic residue, the Mg 2 þ -coordinating D214, vary considerably between structures ( Figure 6B ). The nucleotide ligands also adopt a range of conformations within the active site. Although the adenine and ribose moieties superimpose well (RMSD B0.5 Å ), the relative locations of the three phosphates in AMPCPP differ from ATP, and between distinct AMPCPP molecules in the asymmetric unit ( Figure 6C) .
The peptide structures also show striking conformational variability. In each MccA complex, the C-terminus is not visible for at least one peptide in the asymmetric unit (see Materials and methods). When the C-terminus is present, it is not directed towards the adenylation active site. Thus, the Ca positions of the succinimide and MccA's C-terminus in structures with or without AMPCPP differ by B8 Å ( Figure 6D ). The ability of MccB to bind substrate peptides with a range of conformations, anchored by their N-terminus and backbone carbonyls, likely explains why in vivo substitutions for MccA's residues 2, 4-6 are tolerated for the production of a complete MccC7 variant, but few are accepted for T 3 .
The peptide C-terminal flexibility was unexpected and may be a unique feature of the MccB-MccA system when compared with UBL-activating enzymes. For each of the five structurally determined UBL-activating enzyme complexes, there are 2-21 independent UBL models that superimpose well at their C-termini (Lake et al, 2001; Walden et al, 2003a; Lois and Lima, 2005; Lehmann et al, 2006; Huang et al, 2007; Lee and Schindelin, 2008; Souphron et al, 2008) , and they also superimpose well for the complexes from different pathways. Further studies will be necessary to reveal whether UBL C-termini also display such conformational flexibility in complexes with their activating enzymes, or whether this is a unique feature of the MccB-MccA system. E1-like protein that functions without forming a thioester or an acyl-disulfide intermediate UBL-activating enzymes generally catalyse multiple reactions. After UBL adenylation, subsequent reactions often involve formation of a covalent UBLBenzyme complex, such as a thioester or acyl-disulfide intermediate linked through an activating enzyme thiol (Ciechanover et al, 1981; Haas and Siepmann, 1997; Johnson et al, 1997; Xi et al, 2001; Bohnsack and Haas, 2003; Pickart and Eddins, 2004) , although neither E. coli MoeB nor ThiF from some organisms require such a covalent enzyme-UBL intermediate (Leimkuhler et al, 2001; Park et al, 2003) . To explore the possibility of an acyl-S-enzyme intermediate for MccB, all cysteines not involved in zinc binding (Cys residues 44, 68, 123, 227 and 302) were mutated to alanines (Supplementary Figure 10A) . No MccB Cys is essential for catalysis. One Cys, C123, is located in the Gly-Cys-Gly-Gly-Ile-Gly Walker A motif (Walker et al, 1982) , and thus seems to have a structural function in establishing the nucleotide-binding site (Figure 7) . In other UBL-activating enzymes, the residue corresponding to C123 is either a Leu or a Val, so, therefore, the C123V and C123L mutants were considered. All Cys mutants had similar activity profiles to the WT enzyme (Supplementary Figure 10B) with the exception of C123L and C123V. Conversion of C123 to bulkier, hydrophobic residues caused the succinimide intermediate to be present at higher levels than in reactions with the WT enzyme. Mutation of C123 to a bulkier Leu impaired activity ( Figure 7B ; Table II ). Consistent with the structurally important role of C123, iodoacetamide is inactivating, likely due to an indirect effect on the structure of the adenylation-active site (Figure 7; Supplementary Figure 10) . Thus, unlike E1s and the prokaryotic UBL-activating enzyme ThiF (Xi et al, 2001) , MccB function does not require thiol-mediated catalysis. Intramolecular capture of the nascent peptidyl-AMP is the only kinetically significant outcome.
Prokaryotic variations on E1-UBL themes
Prokaryotic UBL-E1-like complexes, ThiS-ThiF and MoaDMoeB, have long been recognized for their roles in sulphur incorporation into thiazole and molybdopterin, respectively (Rajagopalan, 1997; Begley et al, 1999) . Both ThiS and MoaD structurally resemble UBLs, and are activated by ThiF or MoeB-catalysed adenylation of their C-terminal Gly-Gly sequences. ThiF and MoeB consist exclusively of an adenylation domain (Lake et al, 2001; Duda et al, 2005; Lehmann et al, 2006) , and thus represent minimal modules harbouring UBL recognition and adenylation activities.
The structures of MccB reveal four key features that functionally distinguish its unique properties relative to ThiF, MoeB, and all other UBL-activating enzyme family members. The first two define MccB as a modifier of peptide, and not of a UBL: (1) the B100-residue NTE and (2) an extended crossover loop sequence together form the peptide clamp domain. The second two define MccB as NOT recognizing a C-terminal Gly-Gly motif: (3) the lack of a conserved Arg at MccB's position I220 and (4) the D214-Y239 bridge (Y239 being unique to MccB). This latter characteristic may also contribute to MccB's selectivity for a C-terminal Asn. Interestingly, these features define a large clade of the UBL-activating enzyme family. Database searches revealed that numerous bacterial species have proteins sharing all these hallmark features of MccB . Furthermore, potential paralogues of MccA and downstream components of the MccC7 biosynthetic pathway have also been identified in these same organisms. Notably, relative to the active site sequences, the anticipated peptide-binding residues are poorly conserved among the MccB homologues, and the MccA paralogues also display a range of sequences, while maintaining a C-terminal Asn. Although these enzymes remain uncharacterized, it seems likely that the MccB-like enzymes from many bacteria use a range of starting peptide sequences to generate phosphoramidate-linked analogues of aspartic acid acyl-adenylate.
A recent study identified a novel Mycobacterial UBL, Pup, which like ubiquitin becomes C-terminally conjugated to a target's Lys through an isopeptide linkage (Pearce et al, 2008) . Similar to MccA, Pup's C-terminal residue is not a Gly, but rather a Gln that seems to undergo deamidation during conjugation. No E1 has been identified for Pup. Thus, it seems that prokaryotes use a wide array of variations of UBLs, E1s, or both not only for sulphur incorporation in biosynthetic pathways, but also for a range of posttranslational modifications of proteins (e.g. pupylation) and of peptides for conversion to antibiotics.
Implications for MccB-catalysed production of a phosphoramidate-linked analogue of aspartic acid acyl-adenylate Our structural and biochemical data yielded several insights into a unique member of the UBL-activating enzyme family. MccB can use peptide substrates by virtue of a novel and essential peptide clamp domain. The clamp works in concert with the opposing surface, which is the adenylation domain. Despite similarities to the adenylation-active sites of UBLactivating enzymes, MccB catalyses two adenylation reactions: first on a C-terminal Asn and subsequently on a succinimide moiety to form an N-P bond. Both substrates are directed towards the active site for attack on the ATP a-phosphate and consequent adenylation. The D214A and Y239A mutants are significantly impaired in converting both the first-and secondpeptide substrates to product; a single mutation hinders both adenylation events. In our crystal structures, these residues are poised near the ATP a-phosphate to position the substrate C-termini for adenylation. Therefore, it seems that each adenylation occurs within the same active site.
Although none of the structurally observed peptide C-termini are positioned for catalysis, a catalytically relevant model for the final reaction can be generated by subtle substrate peptide rearrangements. Rotation about the succinimide C-N bond B1801 reduces the catalytic gap within 4 Å (Figure 8) . The model is consistent with a mechanism, whereby the MccB Y239 and the Mg 2 þ ion coordinated by MccB's D214 orient the ATP a-phosphate. On the basis of their relative locations to the a-phosphate, we speculate that D214 and Y239 may form a bridge that positions the MccA C-terminus for the initial reaction. With the Mg 2 þ ion relieving electrostatic repulsion, the MccA C-terminal carboxylate oxygen can first attack the ATP a-phosphate. The Mg 2 þ ion and side chains from MccB R157, Q158, and K170 are poised to stabilize a developing negative charge on the ATP b-phosphate in the anticipated transient pentacovalent phosphate species, allowing resolution to MccA-peptidyladenylate and inorganic pyrophosphate.
Subsequent steps in this antibiotic biosynthetic mechanism are exclusive to MccB, and are not shared by UBLactivating enzymes. The MccB structures reveal features that can accommodate the unique proceeding chemical steps on the nascent peptidyl-AMP. The structurally observed local flexibility at the adenylation-active site likely facilitates having multiple catalytic events occur there after the initial adenylation reaction. These events include the intramolecular closure of the Asn 7 carboxamido nitrogen on the -CO-AMP moiety and collapse of the tetrahedral adduct to expel AMP to generate the succinimide intermediate. This may be released from the enzyme or, given the peptide clamp domain, may react with a second molecule of ATP before dissociation. Exogenous peptidyl-succinimide is chemically and kinetically competent as an intermediate for MccB conversion to the N-P-AMP final product, so that the 'off' and 'on' steps can be fast relative to the second adenylation.
The most remarkable chemical transformation catalysed by MccB is the subsequent transfer of AMP to the succinimido nitrogen. We propose that placement of the peptidylsuccinimide in the active site, secured by MccB's unique peptide clamp, orients the succinimide nitrogen to attack another molecule of ATP that has diffused into the active site. Thus, the peptide clamp domain would allow two adenylation reactions to be performed sequentially: the first with a typical peptide-C-terminal carboxylate oxygen as nucleophile and the second with the succinimide nitrogen as nucleophile. In the proposed mechanism, two canonically weak nucleophiles within the substrate framework are competent. The first is the entropically favoured intramolecular cyclization of the Asn 7 b-carboxamide N on Ca of the peptidyl-AMP nascent product. The second is the intermolecular reaction of the cyclic succinimido nitrogen of Pa of another bound ATP, which creates the unusual N-P linkage that is the hydrolytically stable centrepiece of the antibiotic maturation logic.
Materials and methods
Purification of MccB proteins for activity assays and crystallography
For activity assays, MccB and variants were prepared as described earlier (Supplementary data) (Roush et al, 2008) . Preparation of MccB truncation mutants included a thrombin cleavage step. For crystallographic studies, MccB with a C-terminal His 6 -tag and a cleavable, N-terminal His 6 -tag were purified by Ni 2 þ affinity, anion exchange, and gel filtration chromatography in 20 mM Tris pH 8.0, 150 mM NaCl, and 5 mM DTT. Preparation of MccB lacking the Nterminal His 6 -tag included a thrombin cleavage step after affinity purification. MccB was concentrated to 25-28 mg/ml by ultrafiltration at 41C, aliquoted, flash frozen, and stored at À801C. Peptides for crystallography were synthesized and reverse-phase HPLC purified by the Hartwell Center for Bioinformatics and Biotechnology at St Jude.
Crystallization and data collection
Crystals of MccB-His 6 were grown by hanging drop vapour diffusion at 41C in 100 mM Tris pH 8.0, 2.1 M NaCl 2 , cryoprotected in the mother liquor supplemented with increasing concentrations of glycerol in four steps from 10 to 40% (v/v), and flash frozen in liquid nitrogen for data collection. These crystals form in the space group P2 1 2 1 2 1 with two MccB homodimers in the asymmetric unit. The MccB-His 6 dimers packed so that the C-terminal His 6 -tag of protomers A and C passed under the crossover loops of adjacent protomers D and B, respectively. To prevent a His 6 -tag from interfering with the crossover loop for all complex structures, MccB produced with a cleavable and removed N-terminal His 6 -tag was crystallized. Screens produced crystals in several conditions at 4 and 181C. Crystals in space group P2 1 were grown at 181C by microseeding, with two MccB homodimers per asymmetric unit. The well condition varied depending on the complex; the precipitant was 24-26% pentaerythritol ethoxylate ( Pentaerythritol ethoxylate was a suitable cryoprotectant, so crystals were flash frozen after harvesting directly from the drop. For MccB(MccA-N7isoAsn) and MccB(succinimide), the crystals were soaked in 30% pentaerythritol ethoxylate supplemented with the buffer and additives at the same concentration as in the well, and a higher concentration of peptide ligand, 60 and 20 mM, respectively.
Reflection data were collected at beamlines 8.2.1 and 8.2.2 at The Advanced Light Source and SERCAT 22-ID, 22-BM, and NECAT 24-ID at The Advanced Photon Source and were processed with HKL2000 (Otwinowski and Minor, 1997) .
Structure determination, refinement, and analysis The crystal structure of MccB-His 6 (Apo) was determined to 2.8 Å by three-wavelength Zinc-MAD (Table I) . Four Zn 2 þ sites were located and refined using the program SOLVE (Terwilliger and Berendzen, 1999) . The final Z-score and figure of merit were 30.0 and 0.28, respectively. Density modification of phases from SOLVE was performed with RESOLVE (Terwilliger, 2000) , yielding maps with continuous electron density from the N-to C-termini. The apo model was built manually using the ThiF model as a guide (PDB 1ZFN; Duda et al, 2005) in COOT (Emsley and Cowtan, 2004) and refined against the peak dataset using restrained refinement in REFMAC5 (Murshudov et al, 1997) , with 5% of the reflections set aside as the test set. Placement of side chains was verified with simulated-annealing composite-omit maps calculated with central nervous system (CNS) (Brunger et al, 1998) .
MccB(MccA-N7isoAsn) was determined by molecular replacement with PHASER (McCoy et al, 2007) using the apo dimers A-B and C-D, lacking crossover loops as independent search models. Subsequent complex structures were determined by rigid-body refinement with REFMAC5 using the MccB(MccA-N7isoAsn) structure lacking the peptide, solvent, and crossover loops. Each asymmetric unit can contain four peptides (two for each dimer), and in all structures the N-terminal Met or SeMet was observed in F o -F c maps contoured at 3 s. In addition, the anomalous signal from SeMet-MccA was used to verify the location of the N-terminus of the peptide; 10 s peaks for the SeMet were observed in anomalous maps (Supplementary Figure 3A) . Density extended beyond the N-terminal Met or SeMet for a minimum of one peptide within the asymmetric unit, so that each structure contains at least one peptide modelled from the N-to C-termini. Peptides that were not built completely are truncated. For the nucleotide-bound structures, all four cofactors are modelled. There seems to be a high propensity for anion binding to this region, as additional electron density in the MccB-MccA-N7isoAsn structure localizes to the same relative location as ATP's a-phosphate. We modelled this density as sulphate from NH 4 (SO 4 ) 2 in the crystallization solution. Complex structures were refined with REFMAC5 (Murshudov et al, 1997) using TLS or CNS (Brunger et al, 1998) with the same set of reflections set aside as the test set to avoid biasing the R free . For analysis, all A-B and C-D dimers were superimposed with MultiProt (Shatsky et al, 2004) .
MccB activity assays
Peptides were synthesized through solid-phase peptide synthesis by staff at the Biopolymers Facility, Department of Biochemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA. Their purity and identities were confirmed by HPLC/LCMS. MccA and MccA-N7isoAsn have the sequences MRTGNAN and MRTGNAisoN, respectively. The succinimidyl peptide (MRTGNAsuccinimide) was synthesized as described earlier (Novoa et al, 1986; Roush et al, 2008) .
MccB was incubated with MccA (250 mM) in reaction buffer (75 mM Tris-HCl pH 8.0, 5 mM MgCl 2 , 2.5 mM TCEP, 5 mM ATP). Reactions were quenched by addition of equal volume of 0.6% TFA/H 2 O. Product formation was monitored by analytical HPLC using a gradient of 0-40% B in 8 min with a flow rate of 4 ml/min (solvent A: 0.1% TFA in H 2 O; solvent B: acetonitrile). For a list of all mutants tested, see Supplementary Table I .
Iodoacetamide inactivation of MccB
MccB (5 mM) was incubated in buffer (75 mM Tris-HCl, 5 mM MgCl 2 ) with or without iodoacetamide (5 mM) at 371C for 1 h. Unreacted iodoacetamide was quenched by the addition of 10 mM dithiothreitol. Product formation was monitored after incubation with ATP (5 mM) and MccA (250 mM) at room temperature for 1.5 h.
Kinetic characterization of the MccB-catalysed reaction
The detection limit for HPLC assays was 10 pmol of MccB product, which amounted to a rate of 0.01% of WT enzyme over a 24-h time period. Kinetic investigations were conducted in buffer (75 mM Tris-HCl pH 8.0, 5 mM MgCl 2 , 2.5 mM TCEP). The 100-ml reactions were quenched with equal volume of 0.6% TFA/H 2 O, and product formation was monitored by analytical HPLC. Product peaks (260 nm) were integrated and the resulting values were converted to molecules formed by using an ATP standard curve (62.5-500 mM ATP). Data were fit to the Lineweaver-Burk equation in Microsoft Excel and reported values are the mean±standard deviation of at least three independent trials. For the range of concentrations tested, see Supplementary Tables II and III . 
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